Pemphigoid Gestationis

Overview & Epidemiology - Belly's Blister Blues

• Rare autoimmune blistering disease primarily of pregnancy and puerperium.
• Onset: Usually 2nd/3rd trimester; can be 1st trimester or postpartum.
• Incidence: Approx. 1 in 50,000 pregnancies.
• Patho: IgG autoantibodies against BPAG2 (BP180/collagen XVII) in hemidesmosomes.
• Starts with intense pruritus, often periumbilical, followed by urticarial plaques then vesicles/bullae.

  ⭐ Often recurs earlier and more severely in subsequent pregnancies; may also flare with OCP use or menses later in life.

Pathogenesis - Autoimmune Attack Mode

• Autoimmune: IgG1 autoantibodies, often initiated by placental BP180, cross-react with skin.
• Target Antigen: BP180 (Collagen XVII), specifically its NC16A domain within hemidesmosomes at the dermoepidermal junction (DEJ).
• Mechanism:
  • IgG binding to BP180 (NC16A) → Classical complement pathway activation (C3, C4).
  • Release of C3a, C5a (anaphylatoxins) → Mast cell degranulation.
  • Eosinophil & neutrophil chemotaxis → Proteolytic enzyme release (e.g., elastase, MMPs).
  • Basal keratinocyte damage & dermoepidermal separation → Subepidermal blister formation.

⭐ The NC16A domain of BP180 is the immunodominant pathogenic epitope in Pemphigoid Gestationis.

Clinical Features - Rash & Flare Story

• Onset: Typically 2nd/3rd trimester; can be postpartum.
• Rash Evolution:
  • Starts as intensely pruritic urticarial papules & plaques.
  • Periumbilical area is classic starting point; spreads to trunk, limbs.
  • Face, palms, soles, mucosa usually spared.
  • Progresses to vesicles & tense bullae on erythematous/urticarial base.
• Key Symptom: Severe, unrelenting pruritus.
• Flare Dynamics:
  • Commonly flares near delivery or immediately postpartum (≈75%).
  • Recurs in subsequent pregnancies: often earlier, more severe.
  • May flare with OCP use or menstruation.

⭐ Intense pruritus often precedes visible skin lesions.

Diagnosis - Confirming Suspicions

• Skin Biopsy (Perilesional):
  • Subepidermal blister.
  • Eosinophilic infiltrate in dermis & blister cavity.
  • Papillary dermal edema.
• Direct Immunofluorescence (DIF) - Gold Standard:
  • Linear deposition of C3 (+/- IgG) along Basement Membrane Zone (BMZ).
• Indirect Immunofluorescence (IIF):
  • Detects circulating IgG anti-BMZ antibodies (complement-fixing); ~50-100% positive.
• ELISA:
  • Detects anti-BP180 (BPAG2) autoantibodies, specifically against NC16A domain.

⭐ DIF is the gold standard, revealing linear C3 deposits (and sometimes IgG) along the dermo-epidermal junction (DEJ).

Management & Prognosis - Soothing & Seeing

• Goals: Relieve pruritus, suppress blisters, ensure fetal well-being.
• Management Algorithm:

• Maternal Prognosis:
  • Usually self-limiting postpartum (weeks-months).
  • Recurrence common: 📌 PG recurs with PG (Pregnancy) or Pills (OCPs).
    • Subsequent pregnancies (often earlier, more severe).
    • Oral contraceptive pills (estrogen-containing).
• Fetal Prognosis:
  • Generally good; close monitoring advised.
  • Potential risks: Prematurity, Small for Gestational Age (SGA).
  • Transient neonatal blistering in ~10% (due to maternal IgG transfer); resolves spontaneously.

⭐ Pemphigoid gestationis characteristically flares around delivery or in the immediate postpartum period, requiring vigilant management.

High‑Yield Points - ⚡ Biggest Takeaways

• Autoimmune blistering disease primarily of late pregnancy (2nd/3rd trimester) or the postpartum period.
• Intense pruritus with initial urticarial papules and plaques that progress to tense blisters, often periumbilical.
• Caused by IgG autoantibodies targeting BPAG2 (BP180), a component of epidermal hemidesmosomes.
• Direct immunofluorescence (DIF) reveals linear C3 deposition (± IgG) along the dermoepidermal junction, which is pathognomonic.
• Strongly associated with HLA-DR3 and HLA-DR4; risk of recurrence in subsequent pregnancies.
• Potential fetal risks include preterm birth and small for gestational age (SGA) infants; transient neonatal lesions can occur.
• Management primarily involves topical or systemic corticosteroids based on severity.